The U.S. Food and Drug Administration (FDA) has granted Priority Review to I-DXd, an investigational antibody-drug conjugate, for the treatment of extensive-stage small cell lung cancer (ES-SCLC), according to regulatory filings. The designation shortens the review timeline from 10 months to 6 months, with a decision expected by Q4 2024.
I-DXd, developed by Daiichi Sankyo, targets tumors expressing HER2 proteins, a pathway implicated in approximately 30% of SCLC cases. The Priority Review follows positive Phase II trial data showing a 40% objective response rate in heavily pretreated patients, as reported in the Journal of Clinical Oncology last month.
“This reflects the urgent need for new options in SCLC, where survival rates haven’t improved meaningfully in decades,” said an oncology analyst familiar with the application. Current frontline therapies typically extend survival by just 10-12 months.
If approved, I-DXd would become the first HER2-directed therapy for SCLC. However, some researchers caution that real-world efficacy may differ from trial results. “These patients often have rapid disease progression, so durability of response remains a key question,” noted a thoracic cancer specialist at a major academic center.
The FDA’s decision could reshape treatment paradigms for the 30,000 Americans diagnosed annually with ES-SCLC. Analysts project peak sales exceeding $1.5 billion should the drug demonstrate survival benefits in ongoing Phase III trials.